which is better???

[p-ricer]

i have a question on AI's and SERM's. I have got a little bit of tissue underneath my nip and was wondering which would be better to get rid of it. Nolvadex or Letrozole? I am getting ready for my 4th or 5th cycle and I wanted to go ahead and get this stuff out of the way. My cycle is going to consist of tren acetate, winstrol, Turinabol, and test prop.

 

[holy ghost]

get BOTH always have on hand also ADEX is a wise investment

 

[Mavafanculo]

i have a question on aromatase inhibitor's and selective estrogen receptor modulator's. I have got a little bit of tissue underneath my nip and was wondering which would be better to get rid of it. Nolvadex or Letrozole? I am getting ready for my 4th or 5th cycle and I wanted to go ahead and get this stuff out of the way. My cycle is going to consist of trenbolone acetate, winstrol, Turinabol, and test testosterone propionate.

there's plenty of studies demonstrating SERMs (like Nolv.a) can reduce existing gy.no. - anti-a's like Femera - letrozole - /arimidex will help prevent future exacerbation, but apparantly arent effective as a treatment based on the studies I've seen.

Raloxifene is a newer less available S.ERM that's been shown to be more effective at reducing existimng g.yno than N.olva.

also, search out andractim, a topical D.HT cream that has good anecdotal buzz for reducing gy.no .

 

[holy ghost]

bro i want to do a fucking letro and dmso mix for longest time

 

[Mavafanculo]

I havent heard about that one lol - any writeups on it?

 

[AhMadKooL]

letro can be used for pre-existing gyno. Nolva on the otherhand doesn't help with pre-existing gyno it can block gyno when on a cycle.

Your using Tren; so nolva is not a good idea it can aggravate prolactin sides; adex or aromasin which are AI's are better

 

[p-ricer]

thanks for the help. Im pretty sure raloxifine is EVISTA. but anyways any suggestions on the cycle?

 

[Mavafanculo]

Femera - letrozole - can be used for pre-existing gynecomastia. Nolvaldex - tamoxifen citrate - on the otherhand doesn't help with pre-existing gynecomastia it can block gynecomastia when on a cycle.

You have it backwards. If you have any studies to back ^^ up, please post.


1)
Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.
Saltzstein D, Sieber P, Morris T, Gallo J.
Urology San Antonio Research PA, Pasteur Medical Plaza, San Antonio, Texas, USA.

A randomized, double-blind, placebo-controlled multicenter trial involving 107 men receiving bicalutamide ('Casodex') 150 mg/day therapy following radical therapy for prostate cancer assessed tamoxifen ('Nolvadex') 20 mg/day and anastrozole ('Arimidex') 1 mg/day for the prophylaxis and treatment of gynecomastia/breast pain. Tamoxifen, but not anastrozole, significantly reduced the incidence of gynecomastia/breast pain when used prophylactically and therapeutically. Serum testosterone levels increased with tamoxifen relative to placebo but prostate-specific antigen levels declined in all treatment groups. Further studies are needed to define the optimum tamoxifen dose and to assess any impact on cancer control. The use of tamoxifen in this setting remains to be investigated



2)
1: J Pediatr. 2004 Jul;145(1):71-6. Related Articles, Links

Comment in:

* J Pediatr. 2005 Apr;146(4):576; author reply 576-7.
* J Pediatr. 2005 Apr;146(4):576; author reply 576-7.

Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.
Lawrence SE, Faught KA, Vethamuthu J, Lawson ML.
Department of Pediatrics, University of Ottawa, Ontario, Canada.

[email protected]

OBJECTIVES: To assess the efficacy of the anti-estrogens tamoxifen and raloxifene in the medical management of persistent pubertal gynecomastia.

STUDY DESIGN: Retrospective chart review of 38 consecutive patients with persistent pubertal gynecomastia who presented to a pediatric endocrinology clinic. Patients received reassurance alone or a 3- to 9-month course of an estrogen receptor modifier (tamoxifen or raloxifene).

RESULTS: Mean (SD) age of treated subjects was 14.6 (1.5) years with gynecomastia duration of 28.3 (16.4) months. Mean reduction in breast nodule diameter was 2.1 cm (95% CI 1.7, 2.7, P <.0001) after treatment with tamoxifen and 2.5 cm (95% CI 1.7, 3.3, P <.0001) with raloxifene. Some improvement was seen in 86% of patients receiving tamoxifen and in 91% receiving raloxifene, but a greater proportion had a significant decrease (>50%) with raloxifene (86%) than tamoxifen (41%). No side effects were seen in any patients.

CONCLUSION: Inhibition of estrogen receptor action in the breast appears to be safe and effective in reducing persistent pubertal gynecomastia, with a better response to raloxifene than to tamoxifen. Further study is required to determine that this is truly a treatment effect.

PMID: 15238910 [PubMed - indexed for MEDLINE]

3)
Management of physiological gynaecomastia with tamoxifen.
Khan HN, Rampaul R, Blamey RW.
Professorial Unit of Surgery, Department of Surgery, Nottingham City Hospital, Nottingham NG5 1PB, UK.

AIMS: We aimed to confirm suggestions that tamoxifen therapy alone may resolve physiological gynaecomastia. METHODS: A prospective audit of the outcome of tamoxifen routinely given to men with physiological gynaecomastia was carried out at Nottingham. Men referred with gynaecomastia had clinical signs recorded, e.g., type (diffuse 'fatty' or retro-areolar 'lump'), size and possible aetiology. They were offered oral tamoxifen 20mg once daily for 6-12 weeks. On follow-up patients were assessed for complete resolution (CR), partial resolution where patient is satisfied with outcome (PR) or no resolution (NR). Success was either CR or PR. RESULTS: Thirty-six men accepted tamoxifen for physiological gynaecomastia. Median age was 31 (range 18-64). Tenderness was present in 25 (71%) cases. Sixteen men (45%) had 'fatty' gynaecomastia and 20 had 'lump' gynaecomastia. Tamoxifen resolved the mass in 30 patients (83.3%; CR=22, PR=8) and tenderness in 21 cases (84%; CR=0, PR=0). Lump gynaecomastia was more responsive to tamoxifen than the fatty type (100% vs. 62.5%; P=0.0041). CONCLUSIONS: Oral tamoxifen is an effective treatment for physiological gynaecomastia, especially for the lump type.

 

[Mavafanculo]

...Your using trenbolone; so Nolvaldex - tamoxifen citrate - is not a good idea it can aggravate prolactin sides; Arimidex - anastrozole - or aromasin which are aromatase inhibitor's are better

1) the notion that Nolvaldex - tamoxifen citrate - aggravates prolactin sides sounds like a ...... "theory" ..... tossed around here a year or so ago based on some anecdotal reports. There's no direct studies to support it. It was initially based on an incidental mention in ONE off-point study on post-menuposal women stating that Nolvaldex - tamoxifen citrate - upregulated progesterone receptors if I recall. No followup, no on-point studies, no mention of gy.no, no mention of prolactin effects etc

If you're sensitive, better safe than sorry I guess, and take the most conservative approach and avoid Nolvaldex - tamoxifen citrate - for prevention.

2) in any event, my response was to his question of getting rid of his existing gyn.o. Going forward, he'll be taking winn.y with the T.ren, which will compete for binding at the progesterone receptor minimizing the possibility of prolactin release.

If he starts to get red swollen nips, or discharge, he can get some dostinex/cabasser (.5mg 2x a week), and/or also take B-6 prophalactically (research the dose).